astrazeneca oral glp 1 AstraZeneca's GLP-1 scored phase 2 wins, but no data yet AstraZeneca to advance in-licensed oral

A Crowded Pipeline Means Strategic Differentiation Is Critical With over 100 assets in clinical development, ranging from multi-agonists like retatrutide (with potential for ~25% weight loss) to oral small molecules like orforglipron , the battle for clinical and commercial leadership will be intense [3]

Interestingly, a large meta-analysis that included data from 34,043 individuals with NAFLD, who were diagnosed either with imaging studies or histological evidence and were followed over a median period of 6.9 years, suggested that there was a 64% higher risk for experiencing both fatal and nonfatal cardiovascular events vs

She said, When I got home later in the evening, all the meals were still perfectly refrigerated

The effects of glucose levels on the secretion of insulin and glucagon can be managed by glucagon-like peptide-1 (GLP-1) analogs

Risk factors that might warrant consideration of medication adjustment include: Recent initiation or dose escalation of GLP-1 therapy Significant gastrointestinal symptoms (nausea, vomiting, early satiety) Maximum medication doses Known gastroparesis or other conditions affecting gastric emptying For patients where holding the medication is deemed appropriate, the duration should be individualized based on the specific medication, patient factors, and clinical judgment

Use of GLP1RA with demonstrated cardiovascular benefits should be preferred in patients with CKD and T2DM to further reduce cardiovascular risk